Cereius Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Cereius General Information

Description

Developer of radiotherapy techniques intended to treat solid tumor brain metastasis. The company's techniques increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to treat the brain metastasis of patients and improve their chances of survival.

Contact Information

Website
www.cereius.io
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 701 West Main Street
  • Suite 200
  • Durham, NC 27701
  • United States
+1 (919)
Primary Industry
Drug Discovery
Corporate Office
  • 701 West Main Street
  • Suite 200
  • Durham, NC 27701
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cereius Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 22-Jun-2023 Completed Pre-Clinical Trials
2. Debt - General 12-Feb-2020 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 25-Jul-2018 $6.75M $6.75M Completed Pre-Clinical Trials
To view Cereius’s complete valuation and funding history, request access »

Cereius Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3
Series A2
Series A1 916,190 $0.000100 6% $0.58 $0.58 1x $0.58 8.95%
To view Cereius’s complete cap table history, request access »

Cereius Patents

Cereius Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023276697-A1 Her2-binding agents and uses thereof Pending 23-May-2022
EP-4529540-A1 Her2-binding agents and uses thereof Pending 23-May-2022
JP-2025522306-A Her2-binding agents and uses thereof Pending 23-May-2022
US-20260184811-A1 Her2-binding agents and uses thereof Pending 23-May-2022
WO-2023230488-A1 Her2-binding agents and uses thereof Inactive 23-May-2022 C07K16/32
To view Cereius’s complete patent history, request access »

Cereius Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mission BioCapital Venture Capital Minority
To view Cereius’s complete investors history, request access »

Cereius FAQs

  • When was Cereius founded?

    Cereius was founded in 2017.

  • Where is Cereius headquartered?

    Cereius is headquartered in Durham, NC.

  • What industry is Cereius in?

    Cereius’s primary industry is Drug Discovery.

  • Is Cereius a private or public company?

    Cereius is a Private company.

  • What is Cereius’s current revenue?

    The current revenue for Cereius is .

  • How much funding has Cereius raised over time?

    Cereius has raised $7.25M.

  • Who are Cereius’s investors?

    Mission BioCapital has invested in Cereius.

  • When was Cereius acquired?

    Cereius was acquired on 22-Jun-2023.

  • Who acquired Cereius?

    Cereius was acquired by Solve Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process